Results 1 to 2 of 2

Thread: Besnier, et al. (2002). Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study.

  1. #1

    Besnier, et al. (2002). Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study.

    • Besnier DP, Chabannes D, Mussini JM, Dupas B and Esnault VL (2002). Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed 18:36-41. Summary: BACKGROUND/PURPOSE: Extracorporeal photochemotherapy (ECP) has been proposed for the treatment of various auto- and allo-immune reactions. However, a standard ECP regimen did not significantly alter the course of chronic progressive multiple sclerosis (MS). We tested whether an intensive ECP treatment can affect the course of secondary chronic progressive form of MS. METHODS: Five patients free of immunosuppression were included. Soluble 8-MOP was added ex vivo to a mononuclear cell suspension obtained in a cell separator. This cellular suspension was then irradiated using an UVA irradiator and re-infused into the patient. ECP was performed once a week for 6 weeks and then, depending on clinical evaluation, for a maximum of 6 months, with 2-year follow-up after treatment discontinuation. Scoring was performed with the Kurzke scale and EDSS by a single independent neurologist. RESULTS: One patient was excluded because of recurrent attacks at the very beginning of treatment. Four patients completed the study: one exhibited clinical improvement and three remained stable during the first 6 months of treatment. However, all experienced relapse or worsening of the disease after discontinuation of ECP treatment. CONCLUSION: Our intensive ECP treatment only transiently alters the course of the severe secondary chronic progressive form of MS, with rebound after treatment discontinuation. Department of Nephrology, Nantes University Hospital, 44093 Nantes, France.

  2. #2
    Banned Acid's Avatar
    Join Date
    Dec 2002
    Location
    Berlin
    Posts
    1,779

    Hmm

    "One patient had to be excluded because of a relpase at the beginning." "The authors conclude that this treatment only provided a transient protection."

    If it does, why did it not there.
    What are the natural longest distances between what here we might call like Schuebe?
    Meaning something like, where it gets worse.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •